Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Inventory (2016 - 2026)

Ocular Therapeutix has reported Inventory over the past 13 years, most recently at $3.7 million for Q1 2026.

  • For Q1 2026, Inventory rose 14.32% year-over-year to $3.7 million; the TTM value through Mar 2026 reached $3.7 million, up 14.32%, while the annual FY2025 figure was $3.6 million, 17.24% up from the prior year.
  • Inventory for Q1 2026 was $3.7 million at Ocular Therapeutix, up from $3.6 million in the prior quarter.
  • Over five years, Inventory peaked at $3.7 million in Q1 2026 and troughed at $1.4 million in Q1 2022.
  • A 5-year average of $2.5 million and a median of $2.4 million in 2024 define the central range for Inventory.
  • Biggest five-year swings in Inventory: soared 66.86% in 2023 and later grew 6.56% in 2024.
  • Year by year, Inventory stood at $2.0 million in 2022, then increased by 16.77% to $2.3 million in 2023, then surged by 31.89% to $3.0 million in 2024, then rose by 17.24% to $3.6 million in 2025, then grew by 4.85% to $3.7 million in 2026.
  • Business Quant data shows Inventory for OCUL at $3.7 million in Q1 2026, $3.6 million in Q4 2025, and $3.5 million in Q3 2025.